Moderna | 8-K: Robert Lange and Stephen Berenson Resign from Board of Directors
Moderna | 8-K: Amended and Restated Articles of Incorporation
Moderna | 8-K: Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates
Moderna | DEFA14A: Others
Moderna | DEF 14A: Definitive information statements
Moderna | PRE 14A: Preliminary proxy statements relating to merger or acquisition
Moderna | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Moderna | 8-K: Moderna Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Updates
Moderna | 8-K: Updates of Progress on the Pipeline of Transformative mRNA Medicines and Preliminary Financial Results
Moderna | 8-K: Moderna announces that Arpa Garay Will Leave His Position
Moderna | 8-K: Chief Commercial Officer Arpa Garay Cancelled the Garay 10b5-1 Plan on November 6, 2023
Moderna | 8-K: Moderna Reports Third Quarter 2023 Financial Results
Moderna | 8-K: Moderna Statement on Anticipated 2023 COVID-19 Sales
Moderna | 8-K: Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
Moderna | 8-K: Moderna Reports Second Quarter 2023 Financial Results
Moderna | 8-K: Notice of the 2023 Annual Meeting of Stockholders
Moderna | S-3ASR: Automatic shelf registration statement of securities of well-known seasoned issuers
Moderna | 8-K: Moderna Reports First Quarter 2023 Financial Results
Moderna | DEFA14A: Others
Moderna | DEFA14A: Others
No Data